E
BioNxt Solutions Inc. BNXTF
$0.3747 $0.0257.15%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 8/30/2024Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 8/30/2024 due to a decline in the volatility index.
D
Sell 8/15/2024Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 8/15/2024 due to an increase in the volatility index and valuation index.
E
Sell 7/25/2024Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 7/25/2024 due to a decline in the volatility index and total return index.
D
Sell 7/10/2024Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 7/10/2024 due to an increase in the volatility index.
E
Sell 6/24/2024Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 6/24/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.1 to 0.03, and debt to equity increased from -0.9 to -0.84.
D
Sell 12/28/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 12/28/2023 due to an increase in the volatility index.
E
Sell 12/13/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 12/13/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell 11/28/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 11/28/2023 due to an increase in the growth index, volatility index and total return index. EBIT increased 45.95% from -$1.49M to -$805.1, earnings per share increased from -$0.0178 to -$0.0106, and operating cash flow increased 10.6% from -$899.1 to -$803.8.
E
Sell 11/21/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 11/21/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell 11/6/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 11/6/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell 10/10/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 10/10/2023 due to a decline in the volatility index and total return index.
D
Sell 9/25/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 9/25/2023 due to an increase in the volatility index and total return index.
E
Sell 9/5/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 9/5/2023 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 53.84% from -$968.3 to -$1.49M, and earnings per share declined from -$0.0118 to -$0.0178.
D
Sell 8/18/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 8/18/2023 due to an increase in the volatility index.
E
Sell 8/3/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 8/3/2023 due to a decline in the volatility index and total return index.
D
Sell 7/19/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 7/19/2023 due to an increase in the volatility index.
E
Sell 7/3/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D- on 7/3/2023 due to a decline in the volatility index and total return index.
D
Sell 4/17/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D- from E+ on 4/17/2023 due to an increase in the valuation index, total return index and volatility index.
E
Sell 3/14/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
D
Sell 2/9/2023Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell 2/8/2023Downgrade
BioNxt Solutions Inc. (BNXTF) was downgraded to E+ from D on 2/8/2023 due to a large decline in the solvency index, total return index and volatility index.
D
Sell 5/4/2022Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D from E+ on 05/04/2022.
E
Sell 5/3/2022Downgrade
XPhyto Therapeutics Corp. (XPHYF) was downgraded to E+ from D on 5/3/2022 due to a decline in the volatility index.
D
Sell 4/29/2022Upgraded
XPhyto Therapeutics Corp. (XPHYF) was upgraded to D from D- on 4/29/2022 due to an increase in the volatility index.
D
Sell 4/20/2022Downgrade
XPhyto Therapeutics Corp. (XPHYF) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
D
Sell 11/9/2021Upgraded
BioNxt Solutions Inc. (BNXTF) was upgraded to D from E+ on 11/09/2021.
E
Sell 11/8/2021Downgrade
XPhyto Therapeutics Corp. (XPHYF) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 3.53 to 1.69, and debt to equity increased from 0.5 to 0.74.
D
Sell 12/1/2020Upgraded
XPhyto Therapeutics Corp. (XPHYF) was upgraded to D from D- on 12/1/2020 due to an increase in the solvency index and valuation index. Debt to equity declined from 0.08 to 0.05.
D
Sell 8/3/2020Upgraded
XPhyto Therapeutics Corp. (XPHYF) was upgraded to D- from E+ on 8/3/2020 due to an increase in the valuation index and solvency index. The quick ratio increased from 0.43 to 2.13.
E
Sell 5/1/2020Upgraded
XPhyto Therapeutics Corp. (XPHYF) was upgraded to E+ from E on 5/1/2020 due to a major increase in the total return index and growth index. Total revenue increased 262.17% from $34.1 to $123.5, EBIT increased 53.58% from -$2.82M to -$1.31M, and earnings per share increased from -$0.0596 to -$0.0336.
E
Sell 2/24/2020None
BioNxt Solutions Inc. (BNXTF) was downgraded to E from U on 02/24/2020.
Weiss Ratings